NCT04113239

Brief Summary

A case-control study to identify microbiome and genetic differences between healthy people and patients with incident type 2 diabetes mellitus.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
200

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Nov 2019

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

October 1, 2019

Completed
1 day until next milestone

First Posted

Study publicly available on registry

October 2, 2019

Completed
2 months until next milestone

Study Start

First participant enrolled

November 27, 2019

Completed
1.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 20, 2021

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

November 25, 2021

Completed
Last Updated

July 20, 2022

Status Verified

February 1, 2021

Enrollment Period

1.9 years

First QC Date

October 1, 2019

Last Update Submit

July 19, 2022

Conditions

Keywords

Gut MetageneticsDiabetes Mellitus, Type 2GeneticsMicrobiomeFFQGPAQ

Outcome Measures

Primary Outcomes (4)

  • HbA1C

    Glycated hemoglobin level

    Baseline

  • Glucose

    Fasting blood glucose level

    Baseline

  • Gut microbiome composition of participants

    Bacteria abundance obtained via sequencing the DNA extracted from the stool sample

    Baseline

  • Genotypes of participants

    Genotypes of thousands of SNPs obtained via DNA-microarray genotyping of the DNA extracted from the saliva sample

    Baseline

Secondary Outcomes (2)

  • Physical activity questionnaire

    Baseline

  • Food frequency questionnaire

    12 months before baseline

Study Arms (2)

Diagnosed Type 2 Diabetes Mellitus

Patients with incident type 2 diabetes mellitus

Diagnostic Test: 16S rRNA gene sequencingGenetic: DNA-microarray genotyping

Control

Volunteers without diagnosed type 2 diabetes mellitus and who don't meet the exclusion criteria

Diagnostic Test: 16S rRNA gene sequencingGenetic: DNA-microarray genotyping

Interventions

Taking a stool sample for gut microbiome DNA sequencing

ControlDiagnosed Type 2 Diabetes Mellitus

Taking a saliva sample for genotyping

ControlDiagnosed Type 2 Diabetes Mellitus

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Healthy volunteers and patients with incident type 2 diabetes mellitus from Russia, Moscow

You may qualify if:

  • Confirmed diagnosis of incident type 2 diabetes mellitus

You may not qualify if:

  • Hypoglycaemic therapy prescribed for the correction of any type of hyperglycaemia
  • Diabetic ketoacidosis
  • Inflammatory bowel diseases (ulcerative colitis, Crohn's disease, coeliac disease)
  • Rheumatoid arthritis
  • Tuberculosis
  • Acute gastrointestinal conditions
  • Irritable bowel syndrome
  • Multiple intestinal polyposis
  • Gallstone disease
  • Acute pancreatitis
  • Oncological diseases
  • Serious mental disorders
  • Recent (\< 6 months) antimicrobial therapy
  • Recent (\< 3 months) proton pump inhibitors therapy
  • Recent (\< 3 months) surgical intervention
  • +4 more criteria

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

City Clinical Hospital V.P. Demikhova

Moscow, Russia

Location

MeSH Terms

Conditions

Diabetes Mellitus, Type 2Genetic Predisposition to Disease

Condition Hierarchy (Ancestors)

Diabetes MellitusGlucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesEndocrine System DiseasesDisease SusceptibilityDisease AttributesPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
CROSS SECTIONAL
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

October 1, 2019

First Posted

October 2, 2019

Study Start

November 27, 2019

Primary Completion

October 20, 2021

Study Completion

November 25, 2021

Last Updated

July 20, 2022

Record last verified: 2021-02

Data Sharing

IPD Sharing
Will not share

Locations